Skip to main content

Analysts Conflicted on These Healthcare Names: Mettler-Toledo (MTD), Nuvation Bio (NUVB) and Mereo Biopharma Group Plc (MREO)

Tipranks - Tipranks - Wed Feb 11, 7:46AM CST

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Mettler-Toledo (MTD – Research Report), Nuvation Bio (NUVB – Research Report) and Mereo Biopharma Group Plc (MREO – Research Report).

Valentine's Day Sale - 70% Off

Mettler-Toledo (MTD)

Morgan Stanley analyst Kallum Titchmarsh maintained a Hold rating on Mettler-Toledo today and set a price target of $1475.00. The company’s shares closed last Monday at $1380.88.

According to TipRanks.com, Titchmarsh is a 3-star analyst with an average return of 4.6% and a 42.4% success rate. Titchmarsh covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Adaptive Biotechnologies, and Tempus AI, Inc. Class A. ;'>

Currently, the analyst consensus on Mettler-Toledo is a Moderate Buy with an average price target of $1486.86, an 8.5% upside from current levels. In a report issued on February 7, TipRanks – Google also downgraded the stock to Hold with a $1456.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Nuvation Bio (NUVB)

Wedbush analyst David Nierengarten maintained a Buy rating on Nuvation Bio today and set a price target of $11.00. The company’s shares closed last Monday at $5.64.

According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of 15.4% and a 49.2% success rate. Nierengarten covers the Healthcare sector, focusing on stocks such as BridgeBio Oncology Therapeutics, Artiva Biotherapeutics, Inc., and Perspective Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nuvation Bio with a $12.11 average price target, implying an 111.7% upside from current levels. In a report issued on January 27, TipRanks – Google also initiated coverage with a Buy rating on the stock with a $6.00 price target.

Mereo Biopharma Group Plc (MREO)

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Mereo Biopharma Group Plc yesterday and set a price target of $3.00. The company’s shares closed last Monday at $0.39.

According to TipRanks.com, Kluska is a 5-star analyst with an average return of 26.3% and a 48.5% success rate. Kluska covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Ultragenyx Pharmaceutical, and Lexeo Therapeutics, Inc. ;'>

Currently, the analyst consensus on Mereo Biopharma Group Plc is a Strong Buy with an average price target of $1.75.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).